- American City Business Journals•4 hours ago
AstraZeneca entered into an agreement to sell the rights to a cancer drug in the United States and Canada to TerSera Therapeutics for an upfront payment of $250. The deal could also net AstraZeneca up to $70 million in sales-related income if revenue milestones are met, along with recurring quarterly sales-based payments that are set at a mid-teen percent of product sales. TerSera Therapeutics, which has offices in Iowa and Illinois, acquired the rights to Zoladex, an injectable drug used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
- Zacks•6 hours agoThe Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson
- Market Realist•yesterday
Sanofi has reorganized its diabetes and cardiovascular franchise, making it one of the largest revenue contributors to the pharmaceutical business.
AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance
AstraZeneca PLC (AZN)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||28.87 - 29.13|
|52 Week Range||25.55 - 35.04|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.07|
|Dividend & Yield||1.90 (6.52%)|
|1y Target Est||N/A|